Department of Pharmacology, Wroclaw Medical University & 4th Military Hospital in Wroclaw, Mikulicza-Radeckiego 2, PL 50-345 Wrocław, Poland.
Pharmacol Rep. 2013;65(1):122-33. doi: 10.1016/s1734-1140(13)70970-8.
We evaluated effect of ezetimibe on selected parameters determining NO level in rat liver subjected to ischemia reperfusion (IR).
Rats received ezetimibe (5 mg/kg) (groups E0 and EIR) or saline solution (groups C0 and CIR) intragastrically for 21 days. Then, the livers of CIR and EIR underwent ischemia (60 min) and reperfusion (4 h). Blood samples were obtained before surgery to estimate activities of aminotransferases, and just before ischemia and during reperfusion to estimate asymmetric and symmetric dimethylarginine (ADMA, SDMA) and arginine (Arg) levels. After IR, dimethylarginine dimethylaminohydrolase (DDAH) activity and endothelial nitric oxide synthase (eNOS) protein concentration were measured in liver homogenates. DDAH and protein arginine methyltransferase (PRMT) mRNA were quantified by real-time PCR in liver tissue samples.
In CIR, the ADMA level was significantly higher compared to all other groups in 30 min and to E0 group in 120 min of reperfusion. In EIR, ADMA was low, compared to non-ischemic groups. At 30 and 120 min of reperfusion, in non-ischemic groups the level of Arg and Arg/ADMA ratio were significantly higher than in ischemic groups and E0 was the group with the highest levels of those parameters of all. In CIR, eNOS protein concentration was significantly lower than in ezetimibe-treated groups. Activity of DDAH was significantly higher in E0 than in non-treated groups. In ischemic groups, DDAH mRNA expression was significantly higher than in non-ischemic ones and PRMT mRNA expression was significantly higher in C0 than in all other groups.
Influence of ezetimibe on ADMA/DDAH/NO pathway demonstrated in this work may suggest protective properties of this drug on rat livers injured by IR and, to a lower extent, on livers non-subjected to IR.
我们评估了依泽替米贝对缺血再灌注(IR)大鼠肝脏中决定 NO 水平的选定参数的影响。
大鼠经胃内给予依泽替米贝(5mg/kg)(E0 组和 EIR 组)或生理盐水(C0 组和 CIR 组),共 21 天。然后,CIR 和 EIR 组的肝脏经历缺血(60min)和再灌注(4h)。手术前采集血样以评估氨基转移酶活性,并在缺血前和再灌注期间采集血样以评估不对称和对称二甲基精氨酸(ADMA、SDMA)和精氨酸(Arg)水平。IR 后,测量肝匀浆中二甲基精氨酸二甲氨基水解酶(DDAH)活性和内皮型一氧化氮合酶(eNOS)蛋白浓度。通过实时 PCR 定量肝组织样本中的 DDAH 和蛋白精氨酸甲基转移酶(PRMT)mRNA。
在 CIR 中,与所有其他组相比,ADMA 水平在再灌注 30min 时显著升高,在再灌注 120min 时与 E0 组相比显著升高。在 EIR 中,ADMA 水平较低,与非缺血组相比。在再灌注 30min 和 120min 时,非缺血组 Arg 和 Arg/ADMA 比值的水平明显高于缺血组,E0 组是所有组中这些参数水平最高的组。在 CIR 中,eNOS 蛋白浓度明显低于依泽替米贝治疗组。E0 组的 DDAH 活性明显高于未治疗组。在缺血组中,DDAH mRNA 表达明显高于非缺血组,而 C0 组的 PRMT mRNA 表达明显高于其他所有组。
本研究中观察到的依泽替米贝对 ADMA/DDAH/NO 通路的影响可能表明该药物对 IR 损伤的大鼠肝脏具有保护作用,对未受 IR 影响的肝脏的保护作用较小。